Please enable JavaScript to continue using this application.

Compare $ARWR vs $PTGX | Chartloom

Compare

$ARWR vs $PTGX

Arrowhead Pharmaceuticals Inc · Protagonist Therapeutics Inc

ARWR

Arrowhead Pharmaceuticals Inc

PTGX

Protagonist Therapeutics Inc

Compare $ARWR vs $PTGX

Comparing Arrowhead Pharmaceuticals Inc and Protagonist Therapeutics Inc

ARWRArrowhead Pharmaceuticals Inc

PTGXProtagonist Therapeutics Inc

ARWRArrowhead Pharmaceuticals Inc

Market cap

$8.84B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

43.85x

Rev growth (TTM)

16.8%

YTD performance

-7.4%

52W performance

69.9%

FCF yield

-0.8%

PTGXProtagonist Therapeutics Inc

Market cap

$9.24B

P/E (TTM)

123.10x

Forward P/E (NTM)

77.71x

Forward P/S (NTM)

23.74x

Rev growth (TTM)

34.8%

YTD performance

64.9%

52W performance

120.1%

FCF yield

1.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ARWR

PTGX

Detailed metrics comparison

ARWR

Arrowhead Pharmaceuticals Inc

PTGX

Protagonist Therapeutics Inc

Market Cap

ARWR$8.84B

PTGX$9.24B

Enterprise Value

ARWR$10.04B

PTGX$8.82B

Price

ARWR$62.75

PTGX$143.73

P/E Ratio

ARWRN/A

PTGX123.10x

P/S Ratio

ARWR13.20x

PTGX32.78x

EV/Sales

ARWR15.00x

PTGX31.29x

EV/EBITDA

ARWR31.55x

PTGX140.17x

P/B Ratio

ARWR19.48x

PTGX10.77x

P/FCF Ratio

ARWRN/A

PTGX70.79x

EV/FCF

ARWR-133.73x

PTGX67.57x

PEG Ratio

ARWRN/A

PTGX2.95x

Forward P/E (NTM)

ARWRN/A

PTGX77.71x

Forward P/S (NTM)

ARWR43.85x

PTGX23.74x

Revenue (TTM)

ARWR$669M

PTGX$282M

Revenue Growth (YoY)

ARWR16.8%

PTGX34.8%

Forward Rev Growth

ARWR131.3%

PTGX-70.6%

Gross Margin (TTM)

ARWR0.0%

PTGX0.0%

Operating Margin (TTM)

ARWR0.0%

PTGX20.7%

EBITDA Margin (TTM)

ARWR-30.0%

PTGX21.2%

Net Margin (TTM)

ARWR-47.8%

PTGX29.4%

FCF Margin (TTM)

ARWR-11.2%

PTGX46.3%

Net Income (TTM)

ARWR$-320M

PTGX$83M

FCF (TTM)

ARWR$-75M

PTGX$131M

EPS (TTM)

ARWR-$2.23

PTGX$1.17

ROE (TTM)

ARWR-6054.0%

PTGX12.0%

ROA (TTM)

ARWR-1737.0%

PTGX11.2%

ROIC (TTM)

ARWR-2193.0%

PTGX12.0%

Cash

ARWR$51M

PTGX$420M

Debt

ARWR$1.26B

PTGX$0

Net Cash/Debt

ARWR$-1.21B

PTGX$420M

Current Ratio (TTM)

ARWR5.90x

PTGX21.71x

Quick Ratio (TTM)

ARWR5.81x

PTGX21.58x

Debt/Equity (TTM)

ARWR2.70x

PTGX0.00x

Debt/Assets (TTM)

ARWR0.0%

PTGX0.0%

Interest Coverage (TTM)

ARWRN/A

PTGXN/A

Net Debt/EBITDA (TTM)

ARWR0.00x

PTGX0.00x

Beta

ARWR1.34

PTGX1.19

52W Performance

ARWR69.9%

PTGX120.1%

YTD Performance

ARWR-7.4%

PTGX64.9%

% from 52W High

ARWR-34.3%

PTGX-10.6%

% from 52W Low

ARWR81.3%

PTGX119.2%

Asset Turnover (TTM)

ARWR0.36x

PTGX0.38x

FCF Yield (TTM)

ARWR-0.8%

PTGX1.4%

Earnings Yield (TTM)

ARWR-3.6%

PTGX0.9%

Dividend Yield (TTM)

ARWRN/A

PTGXN/A

Rule of 40

ARWR5.6

PTGX81.1

EV/GP/RG

ARWRN/A

PTGXN/A

Ticker research

View ARWR research View PTGX research

Metric	ARWR Arrowhead Pharmaceuticals Inc	PTGX Protagonist Therapeutics Inc
Market & Valuation
Market Cap	$8.84B	$9.24B
Enterprise Value	$10.04B	$8.82B
Price	$62.75	$143.73
P/E Ratio	N/A	123.10x
P/S Ratio	13.20x	32.78x
EV/Sales	15.00x	31.29x
EV/EBITDA	31.55x	140.17x
P/B Ratio	19.48x	10.77x
P/FCF Ratio	N/A	70.79x
EV/FCF	-133.73x	67.57x
PEG Ratio	N/A	2.95x
Forward P/E (NTM)	N/A	77.71x
Forward P/S (NTM)	43.85x	23.74x
Revenue & Growth
Revenue (TTM)	$669M	$282M
Revenue Growth (YoY)	16.8%	34.8%
Forward Rev Growth	131.3%	-70.6%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	20.7%
EBITDA Margin (TTM)	-30.0%	21.2%
Net Margin (TTM)	-47.8%	29.4%
FCF Margin (TTM)	-11.2%	46.3%
Net Income (TTM)	$-320M	$83M
FCF (TTM)	$-75M	$131M
EPS (TTM)	-$2.23	$1.17
ROE (TTM)	-6054.0%	12.0%
ROA (TTM)	-1737.0%	11.2%
ROIC (TTM)	-2193.0%	12.0%
Financial Health
Cash	$51M	$420M
Debt	$1.26B	$0
Net Cash/Debt	$-1.21B	$420M
Current Ratio (TTM)	5.90x	21.71x
Quick Ratio (TTM)	5.81x	21.58x
Debt/Equity (TTM)	2.70x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.34	1.19
52W Performance	69.9%	120.1%
YTD Performance	-7.4%	64.9%
% from 52W High	-34.3%	-10.6%
% from 52W Low	81.3%	119.2%
Efficiency & Yields
Asset Turnover (TTM)	0.36x	0.38x
FCF Yield (TTM)	-0.8%	1.4%
Earnings Yield (TTM)	-3.6%	0.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	5.6	81.1
EV/GP/RG	N/A	N/A
Ticker research	View ARWR research	View PTGX research

Valuation

P/E Ratio

PTGX

123.10x

P/S Ratio

ARWR

13.20x

PTGX

32.78x

EV/FCF

ARWR

-133.73x

PTGX

67.57x

Growth & revenue

Revenue Growth TTM

PTGX

34.8%

ARWR

16.8%

Forward Revenue Growth

ARWR

131.3%

PTGX

-70.6%

Profitability & performance

Gross Margin

ARWR

0.0%

PTGX

0.0%

ROE

PTGX

12.0%

ARWR

-6054.0%

FCF Yield %

PTGX

1.4%

ARWR

-0.8%

52-Week Performance

PTGX

120.1%

ARWR

69.9%

Detailed metrics comparison

ARWR

Arrowhead Pharmaceuticals Inc

PTGX

Protagonist Therapeutics Inc

Market Cap

ARWR$8.84B

PTGX$9.24B

Enterprise Value

ARWR$10.04B

PTGX$8.82B

Price

ARWR$62.75

PTGX$143.73

P/E Ratio

ARWRN/A

PTGX123.10x

P/S Ratio

ARWR13.20x

PTGX32.78x

EV/Sales

ARWR15.00x

PTGX31.29x

EV/EBITDA

ARWR31.55x

PTGX140.17x

P/B Ratio

ARWR19.48x

PTGX10.77x

P/FCF Ratio

ARWRN/A

PTGX70.79x

EV/FCF

ARWR-133.73x

PTGX67.57x

PEG Ratio

ARWRN/A

PTGX2.95x

Forward P/E (NTM)

ARWRN/A

PTGX77.71x

Forward P/S (NTM)

ARWR43.85x

PTGX23.74x

Revenue (TTM)

ARWR$669M

PTGX$282M

Revenue Growth (YoY)

ARWR16.8%

PTGX34.8%

Forward Rev Growth

ARWR131.3%

PTGX-70.6%

Gross Margin (TTM)

ARWR0.0%

PTGX0.0%

Operating Margin (TTM)

ARWR0.0%

PTGX20.7%

EBITDA Margin (TTM)

ARWR-30.0%

PTGX21.2%

Net Margin (TTM)

ARWR-47.8%

PTGX29.4%

FCF Margin (TTM)

ARWR-11.2%

PTGX46.3%

Net Income (TTM)

ARWR$-320M

PTGX$83M

FCF (TTM)

ARWR$-75M

PTGX$131M

EPS (TTM)

ARWR-$2.23

PTGX$1.17

ROE (TTM)

ARWR-6054.0%

PTGX12.0%

ROA (TTM)

ARWR-1737.0%

PTGX11.2%

ROIC (TTM)

ARWR-2193.0%

PTGX12.0%

Cash

ARWR$51M

PTGX$420M

Debt

ARWR$1.26B

PTGX$0

Net Cash/Debt

ARWR$-1.21B

PTGX$420M

Current Ratio (TTM)

ARWR5.90x

PTGX21.71x

Quick Ratio (TTM)

ARWR5.81x

PTGX21.58x

Debt/Equity (TTM)

ARWR2.70x

PTGX0.00x

Debt/Assets (TTM)

ARWR0.0%

PTGX0.0%

Interest Coverage (TTM)

ARWRN/A

PTGXN/A

Net Debt/EBITDA (TTM)

ARWR0.00x

PTGX0.00x

Beta

ARWR1.34

PTGX1.19

52W Performance

ARWR69.9%

PTGX120.1%

YTD Performance

ARWR-7.4%

PTGX64.9%

% from 52W High

ARWR-34.3%

PTGX-10.6%

% from 52W Low

ARWR81.3%

PTGX119.2%

Asset Turnover (TTM)

ARWR0.36x

PTGX0.38x

FCF Yield (TTM)

ARWR-0.8%

PTGX1.4%

Earnings Yield (TTM)

ARWR-3.6%

PTGX0.9%

Dividend Yield (TTM)

ARWRN/A

PTGXN/A

Rule of 40

ARWR5.6

PTGX81.1

EV/GP/RG

ARWRN/A

PTGXN/A

Ticker research

View ARWR research View PTGX research

Metric	ARWR Arrowhead Pharmaceuticals Inc	PTGX Protagonist Therapeutics Inc
Market & Valuation
Market Cap	$8.84B	$9.24B
Enterprise Value	$10.04B	$8.82B
Price	$62.75	$143.73
P/E Ratio	N/A	123.10x
P/S Ratio	13.20x	32.78x
EV/Sales	15.00x	31.29x
EV/EBITDA	31.55x	140.17x
P/B Ratio	19.48x	10.77x
P/FCF Ratio	N/A	70.79x
EV/FCF	-133.73x	67.57x
PEG Ratio	N/A	2.95x
Forward P/E (NTM)	N/A	77.71x
Forward P/S (NTM)	43.85x	23.74x
Revenue & Growth
Revenue (TTM)	$669M	$282M
Revenue Growth (YoY)	16.8%	34.8%
Forward Rev Growth	131.3%	-70.6%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	20.7%
EBITDA Margin (TTM)	-30.0%	21.2%
Net Margin (TTM)	-47.8%	29.4%
FCF Margin (TTM)	-11.2%	46.3%
Net Income (TTM)	$-320M	$83M
FCF (TTM)	$-75M	$131M
EPS (TTM)	-$2.23	$1.17
ROE (TTM)	-6054.0%	12.0%
ROA (TTM)	-1737.0%	11.2%
ROIC (TTM)	-2193.0%	12.0%
Financial Health
Cash	$51M	$420M
Debt	$1.26B	$0
Net Cash/Debt	$-1.21B	$420M
Current Ratio (TTM)	5.90x	21.71x
Quick Ratio (TTM)	5.81x	21.58x
Debt/Equity (TTM)	2.70x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.34	1.19
52W Performance	69.9%	120.1%
YTD Performance	-7.4%	64.9%
% from 52W High	-34.3%	-10.6%
% from 52W Low	81.3%	119.2%
Efficiency & Yields
Asset Turnover (TTM)	0.36x	0.38x
FCF Yield (TTM)	-0.8%	1.4%
Earnings Yield (TTM)	-3.6%	0.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	5.6	81.1
EV/GP/RG	N/A	N/A
Ticker research	View ARWR research	View PTGX research